United States Patent 9,333,204: Scope of Claims and US Patent Landscape
United States Drug Patent 9,333,204 has a claim set built around one core formulation construct: a two-composition solid dosage form containing amorphous solid dispersions of Compound 1, Compound 2, and ritonavir, paired with a second composition salt form of Compound 4 plus matrix formers. The claims then ladder the dissolution-release profile of Compound 4 across multiple time horizons, while keeping the rest of the formulation and the clinical dosing method relatively fixed (once daily; one or three units per day).
What do the independent claim elements cover?
What is the formulation architecture in the claims?
Across claims 1, 4, 7, 10, 13 (solid dosage forms), the product has two physically defined components (“first composition” and “second composition”) with quantitative constraints and in vitro release requirements.
First composition (common base in claims 1/4/7/10/13):
- Compound 1: 50 mg
- Compound 2: 8.33 mg
- Ritonavir: 33.33 mg
- Copovidone: 70–85% by weight
- Surfactant system: 5–10% by weight of one or more pharmaceutically acceptable surfactants
- Formulation state: Compound 1, Compound 2, and ritonavir are formulated in amorphous solid dispersion
- Weight % are relative to the total weight of the first composition
Second composition (common base in claims 1/4/7/10/13):
- Compound 4 sodium monohydrate salt: 216.2 mg
- Copovidone: 20–40% by weight
- Hypromellose: 20–40% by weight
- Weight % are relative to the total weight of the second composition
Total dosage form mass constraint (common in claims 1/4/7/10/13):
- Total weight: 1200–1400 mg
In vitro dissolution test conditions (common in claims 1/4/7/10/13):
- Medium: 0.05 M sodium phosphate buffer (pH 6.8) + 15 mM cetyltrimethylammonium bromide (cTAB)
- Apparatus: USP Apparatus 2 (paddle)
- Speed: 100 RPM
- Temperature: 37°C
- Volume: 900 mL
Release performance constraints (common test structure, variable time horizons and Compound 4 fractions):
- The claims require a defined percentage release within a given time window for:
- Compound 1
- Compound 2
- Ritonavir
- Compound 4 (with the most detailed tiering across claims)
How do claims 1, 4, 7, 10, and 13 differ?
The set is differentiated primarily by the time-to-release and the release distribution for Compound 4 in the paddle dissolution profile, while leaving the first-composition quantitative composition and the second-composition quantitative inputs consistent.
Claim-specific dissolution release tiers (900 mL, 0.05 M phosphate pH 6.8 + 15 mM cTAB, 100 RPM, 37°C, USP 2)
| Claim (dosage form) |
Timepoint(s) where “Compound 1/2/ritonavir” release is defined |
Compound 1 release |
Compound 2 release |
Ritonavir release |
Compound 4 release distribution required |
| Claim 1 |
≤ 1 hour (all four actives) |
50–60% in 1 hour |
50–60% in 1 hour |
50–60% in 1 hour |
0.5–2% in 1 hour |
| Claim 4 |
≤ 4 hours |
95–100% in 4 hours |
95–100% in 4 hours |
95–100% in 4 hours |
10–15% in 4 hours |
| Claim 7 |
≤ 6 hours |
95–100% in 6 hours |
95–100% in 6 hours |
95–100% in 6 hours |
15–20% in 6 hours |
| Claim 10 |
≤ 8 hours plus additional Compound 4 later split |
100% in 8 hours |
100% in 8 hours |
100% in 8 hours |
20–30% in 8 h; 30–40% in 12 h; 40–60% in 16 h |
| Claim 13 |
≤ 8/12/16/24 hours additional Compound 4 split |
100% in 8 hours |
100% in 8 hours |
100% in 8 hours |
20–30% in 8 h; 30–40% in 12 h; 40–60% in 16 h; 60–80% in 24 h |
Key structural takeaway: Claims 10 and 13 convert Compound 4 release into a staged dissolution curve across multiple time windows. Claims 1/4/7 use a single timepoint rule for all listed percentage release values.
What is the dosing method scope?
Claims 2/3/5/6/8/9/11/12/14/15 are method-of-treatment claims for HCV infection.
They require:
- Administering once daily to a patient in need of treatment
- At least one solid dosage form of the referenced dosage-claim; or
- Three solid dosage forms of the referenced dosage-claim per once-daily dosing
Method dosing ladder by dosage-claim reference
| Method claim |
Dosing quantity per day |
| Claims 2, 5, 8, 11, 14 |
At least one solid dosage form (of claims 1/4/7/10/13 respectively) once daily |
| Claims 3, 6, 9, 12, 15 |
Three solid dosage forms (of claims 1/4/7/10/13 respectively) once daily |
What is the legal and competitive “reach” of these claims?
What does the claim language likely protect strongly?
The claims are tightly constrained to the exact multi-component solid dosage composition and the exact dissolution test conditions, with quantitative ranges for:
- active mass amounts (50 mg, 8.33 mg, 33.33 mg, 216.2 mg)
- polymer and surfactant levels by weight % (copovidone and surfactant)
- formulation state (amorphous solid dispersion of Compound 1/Compound 2/ritonavir)
- total mass (1200–1400 mg)
- dissolution medium chemistry (buffer plus cTAB)
- apparatus and parameters (USP 2, paddle, 100 RPM, 37°C, 900 mL)
- percentage release kinetics, especially for Compound 4 (either strict early-late constraints or multi-time staged constraints)
That combination gives the patent unusually strong product-by-process-ish and product-by-function (dissolution behavior) footholds, even though the chemistry of Compounds is not spelled out in the text you provided.
Where does the claim set leave room for design-around?
The claims lock into specific constraints, so meaningful design-around typically targets at least one of the following claim levers:
-
Break the dissolution test match
- Changing the dissolution medium from 0.05 M phosphate pH 6.8 with 15 mM cTAB or changing the Apparatus/conditions could avoid literal equivalence if performance is judged only under the claimed test.
- The claims are drafted to specific release outcomes under the claimed conditions.
-
Alter the release curve for Compound 4
- Claims 10 and 13 specify multiple timepoints for Compound 4. A competitor that achieves different fractions at 8/12/16/24 hours could avoid those claim limitations.
- Claims 1/4/7 are also narrow on the specific early release fractions (1 hour; 4 hours; 6 hours).
-
Change the form of the second composition
- Second composition is explicitly Compound 4 sodium monohydrate salt (216.2 mg) plus copovidone/hypromellose in specified ranges. If the second composition uses a different salt form, different hydrate state, or different loading, it falls outside literal scope.
-
Remove or change the amorphous solid dispersion requirement
- The claims say Compound 1, Compound 2, and ritonavir are formulated in amorphous solid dispersion. If a formulation keeps crystallinity or uses a different dispersion strategy, it may not meet this limitation.
-
Adjust polymer composition ranges
- First composition copovidone: 70–85%
- First composition surfactant: 5–10%
- Second composition copovidone and hypromellose: each 20–40%
- Competitors can attempt to shift weight percentages outside these windows while still maintaining comparable clinical behavior.
Scope mapping: what product features are required vs optional?
Which elements are “hard requirements” within each dosage claim?
Within each solid dosage claim (1/4/7/10/13), the following are hard requirements:
- A solid dosage form includes first composition + second composition
- First composition contains: 50 mg Compound 1; 8.33 mg Compound 2; 33.33 mg ritonavir
- First composition excipients:
- copovidone 70–85 wt%
- surfactant 5–10 wt%
- First composition: amorphous solid dispersion for Compound 1/2/ritonavir
- Second composition contains:
- 216.2 mg Compound 4 sodium monohydrate salt
- copovidone 20–40 wt%
- hypromellose 20–40 wt%
- Dosage form total weight: 1200–1400 mg
- Dissolution test: 0.05 M phosphate buffer pH 6.8 + 15 mM cTAB, USP 2, 900 mL, 100 RPM, 37°C
- Dissolution release outcomes:
- Compound 1/2/ritonavir each follow the specified release percent by the specified time window(s)
- Compound 4 release follows the specified early or staged release profile
What elements are “flexible” within the claims?
The claims allow flexibility in:
- Surfactant identity: any pharmaceutically acceptable surfactant(s) meeting 5–10 wt% in the first composition
- Copovidone composition distribution within both compositions, subject to the set ranges
- Hypromellose/copolymer ratio in the second composition within 20–40 wt% bounds each
However, the claims do not leave flexibility on:
- active loadings (explicit mg amounts for Compounds 1/2/ritonavir and Compound 4 salt)
- core structural features (two compositions; amorphous solid dispersion; cTAB-containing dissolution medium; release thresholds)
Claim coverage summary (by function)
How does the claim set operationalize a “controlled release” strategy for Compound 4?
Compound 4 is treated as the functional differentiator. The claims impose progressively delayed release profiles:
- Claim 1: Compound 4 release is strongly suppressed early (0.5–2% within 1 hour).
- Claims 4 and 7: Compound 4 releases at moderate levels by 4–6 hours (10–15%, then 15–20%).
- Claims 10 and 13: Compound 4 release becomes a time-fraction split across a longer horizon, with additional staged constraints up to 16 or 24 hours.
In contrast, Compound 1/2/ritonavir release becomes increasingly complete earlier as the claim set moves from Claim 1 to Claims 10/13:
- From 50–60% at 1 hour to essentially full release by 8 hours (100% at 8 hours).
US patent landscape impact: how to read this claim set strategically
Because only the claim text is provided, landscape conclusions can only be drawn at the level of scope behavior (what this patent will likely be used to enforce) and where conflicts will arise (where competitors’ formulation and dissolution curves are expected to overlap).
Where will infringement risk cluster for competitors?
Infringement risk is highest when a competitor’s:
- two-layer dosage form uses amorphous solid dispersions for Compound 1/2/ritonavir
- polymer and surfactant loading matches the constrained ranges
- Compound 4 is delivered as a sodium monohydrate salt at the claimed loading
- dissolution testing under phosphate pH 6.8 + cTAB and USP2 100 RPM 37°C yields the claimed fraction-release profiles at the claimed timepoints
What makes this patent more enforceable than typical formulation patents?
Two drafting choices strengthen enforceability:
- The claims require performance under a very specific dissolution environment including cTAB.
- The claims convert performance into quantified timepoint percentages, especially for Compound 4, turning dissolution data into literal claim metrics.
Key Takeaways
- US 9,333,204 covers a two-composition solid dosage form with exact active loadings and polymer/surfactant windows, where Compound 1/Compound 2/ritonavir are amorphous solid dispersions.
- The practical differentiator across claims is Compound 4 release kinetics under USP2 (paddle), 100 RPM, 37°C, 900 mL, in 0.05 M phosphate buffer pH 6.8 with 15 mM cTAB.
- The claim set escalates from early suppressed Compound 4 release (Claim 1) to multi-time staged Compound 4 release (Claims 10 and 13) while driving Compound 1/2/ritonavir toward complete release by later timepoints.
- Method-of-treatment claims cover once-daily dosing with either 1 or 3 units of the claimed dosage forms for HCV infection.
FAQs
1) What is the dissolution medium specified by US 9,333,204?
0.05 M sodium phosphate buffer (pH 6.8) with 15 mM cetyltrimethylammonium bromide (cTAB).
2) What apparatus and test conditions are required?
USP Apparatus 2 (paddle), 100 RPM, 37°C, 900 mL dissolution medium.
3) Which component is used to create the longest controlled release profile?
Compound 4 (required release fractions at multiple timepoints, especially in Claims 10 and 13).
4) Does the patent cover different dosing regimens by the number of units?
Yes. Method claims require once daily dosing using either at least one or three solid dosage forms, depending on the specific claim reference.
5) What formulation state is explicitly required for the first composition actives?
Compound 1, Compound 2, and ritonavir must be formulated in amorphous solid dispersion.
References
[1] United States Patent 9,333,204, claim text provided by user.
